• induce remission
  • 7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not always the case). (wikipedia.org)
  • The goal is to induce remission initially with medications, followed by the administration of maintenance medications to prevent a relapse of the disease. (wikipedia.org)
  • treatment
  • At a practical level an additional treatment that does not involve corticosteroids and does not suppress the immune system would be available for induction of remission. (clinicaltrials.gov)
  • After initiation of IFN-α treatment, the median PSL dosages could be reduced from 17.5 mg/day at baseline to 5.5 mg/day at time of remission. (jrheum.org)
  • IFN-α treatment results in high rate of remission and maintenance in EGPA with significant reduction in oral corticosteroids, although reversible adverse events may occur. (jrheum.org)
  • Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients? (semanticscholar.org)
  • patients
  • Following remission induction, patients typically require 2-3 weeks for bone marrow blood cell production to recover. (unm.edu)
  • Patients who are deemed at high or very high risk of relapse with standard therapy often receive four or more drugs in the induction regimen. (unm.edu)
  • The response and remission rates between the patients with concomitant steroid, biologic or tacrolimus and without concomitant medication were 80.6% and 70.9% (P=0.28), 61.3% and 53.1% (P=0.13), respectively. (ecco-ibd.eu)
  • All 12 cases responded to cytapheresis, notably, 4 EN patients showing rapid remission after the first 2 cytapheresis sessions. (ecco-ibd.eu)
  • 6 patients had relapse, of which 5 had further cyclophosphamide and two achieved remission. (bmj.com)
  • 30% of patients (15/50) were able to stop immunosuppression while maintaining remission. (bmj.com)
  • Preliminary data in pediatric patients with short duration of disease have shown a remission rate of 60% and normalization of CRP in about 50% of patients treated with azithromycin and metronidazole in combination. (clinicaltrials.gov)
  • The investigators also hypothesize that remission will be accompanied by normalization of CRP in a high proportion of patients with active CD. (clinicaltrials.gov)
  • At baseline, the median BVAS was 6 (interquartile range 4-13.5) and remission or partial response was achieved in 25/30 patients. (jrheum.org)
  • dose
  • 50% had IV glucocorticoids and cyclophosphamide (dose from 500mg-1gm as per weight) for induction therapy. (bmj.com)
  • Importance and anticipated outcomes: The investigators believe that high dose azithromycin will be associated with a high remission rate in early disease. (clinicaltrials.gov)
  • regimen
  • Adults with Philadelphia chromosome-positive ALL usually receive Gleevec® (imatinib), a tyrosine kinase inhibitor, in the induction regimen. (unm.edu)
  • The addition of vinca alkaloids (vincristine or vinblastine) to the "7+3" regimen, which addition was quite popular in AML in old times (when the biology of AML and the differences between AML and ALL was poorly understood) proved to be harmful in AML, lowering the chance of the patient to get remission. (wikipedia.org)
  • It gave rise to the so-called ADE (or DAE = DA + etoposide) induction regimen in AML. (wikipedia.org)
  • response
  • Participants who complete the study, or do not meet protocol response or remission criteria at Week 10 will have the option to enter a separate long-term extension (LTE) study (Gilead Study GS-US-419-3896). (mayo.edu)
  • Interferon-α (IFN-α) can reverse the underlying Th2-driven immune response and has successfully induced remission in previous reports. (jrheum.org)
  • high
  • Conclusions Cyclophosphamide and glucocorticoids have achieved high remission rates 80% (24/30), compared to Lane et al 1 (78% at 5 years). (bmj.com)
  • include
  • Drugs used during remission induction usually include Oncovin® (vincristine), Elspar® (L-asparaginase) or Oncaspar® (peg-L-asparaginase), and an anthracycline such as Adriamycin® (doxorubicin). (unm.edu)